Because Rgs16 suppresses CD8+ T-cell anti-tumor function by decreasing ERK activation and alters patients’ responses to immune checkpoint inhibition, this mechanism may have potential chemotherapeutic implications. The gene discussed is CD8A; the disease is neoplasm.